SXTP — 60 DEGREES PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1946563 ·
Last close
$0.53
Market Cap
$1.88M
52W High
$8.62
52W Low
$0.46
ADV30
687,422
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 207,898 | 56,798 | -2,271,102 | -2,264,526 | 4,282,694 | 1,022,606 | 1,754,271 |
| Mar 2026 | 162,092 | 76,377 | -2,094,961 | -2,089,214 | 6,763,346 | 3,337,760 | 2,018,867 |
| Dec 2025 | 303,385 | 182,703 | -1,917,351 | -1,438,559 | 5,366,211 | 1,510,065 | 1,986,795 |
| Sep 2025 | 437,602 | -100,088 | -2,325,525 | -2,316,324 | 6,689,344 | 4,115,779 | 2,342,386 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,774,808
Investing CF
$-288,342
Financing CF
$8,110,544
CapEx
$-288,342
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.71
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-52,246,855
Inventory
$877,945
Receivables
$567,040
ST Investments
$0
EBIT TTM
$-8,105,812
Pretax Income TTM
$-8,113,398
Interest Exp TTM
$7,586
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,214,931
EBITDA
$-8,504,303
Free Cash Flow
$-6,081,180
Enterprise Value
$11,775,539
Total Cash
$1,022,606
Total Debt
$151,179
Shares Out
3,516,988
Trailing EPS
$-2.67
Book Value
$-2.62
ROE
-332.9%
ROA
-127.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,005,471 | -7,758,579 | -7,365,158 | 5,366,211 | 1,986,795 | 3,463,177 | -6,849,022 |
| Dec 2024 | 607,574 | -9,715,181 | -7,947,107 | 5,759,345 | 1,804,339 | 4,035,600 | -5,648,088 |
| Dec 2023 | 253,573 | -5,154,583 | -3,765,702 | 7,783,771 | 2,985,675 | 4,870,134 | -4,542,910 |
| Dec 2022 | 223,208 | -1,750,445 | -6,181,720 | 1,297,206 | 25,446,266 | -23,576,740 | -1,009,980 |
TTM Snapshot
Revenues TTM
$1,110,977
NetIncome TTM
$-8,108,623
OpCashFlow TTM
—
Assets (Latest)
$4,282,694
Forward EPS
$-3.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACUT | Accustem Sciences Inc. | $1.90M | $0.12 | — |
| XRTX | XORTX Therapeutics Inc. | $1.93M | $1.06 | — |
| PPCB | Propanc Biopharma, Inc. | $1.94M | $1.88 | — |
| JAGX | Jaguar Health, Inc. | $1.96M | $0.38 | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | $2.00M | $1.52 | — |
News headlines (Yahoo Finance, 1h cache)
Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization
2026-11-04 21:15 · Yahoo
60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
2026-10-28 12:30 · Yahoo
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
2026-10-27 12:06 · Yahoo
60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting
2026-10-06 14:44 · Yahoo
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
2026-10-06 12:10 · Yahoo
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-10-02 13:00 · Yahoo
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
2026-10-01 12:03 · Yahoo
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
2026-08-14 19:47 · Yahoo
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
2026-07-08 12:01 · Yahoo
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
2026-07-01 12:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.